Johnson & Johnson said it now expected total 2024 sales of $89.2-billion to $89.6-billion, compared with its prior forecast of $88.7-billion to $89.1-billion
beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.Revenue of $22.4-billion surpassed the consensus estimate of $22.3-billion, according to LSEG data. Adjusted earnings of $2.82 per share beat analysts’ expectations of $2.70 per share.
J&J also lowered its annual per-share forecast to a range of $10 to $10.10 from $10.60 to $10.75, to account for a 5-cent increase from improved performance and a decrease of 68 cents related to costs from mergers and acquisitions including its $13-billion purchase of cardiac medical device company Shockwave.
Analysts expect Stelara sales of more than $10-billion this year, but this could fall to about $7-billion in 2025 when as many as six close copies of the drug are due to launch in the U.S. Darzalex, a blood cancer therapy launched in 2015, is expected to bring in sales of more than $11-billion for J&J this year, analysts said.
Estimate Drug Johnson Sales Share Revenue Analysts J&J Belgium New Jersey
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Wall Street reaches perfect equilibrium of indecision on gold prices, Main Street maintains optimistic outlookThe Kitco News Team brings you the latest news, videos, analysis and opinions regarding Precious Metals, Crypto, Mining, World Markets and Global Economy.
Read more »
Bank of America leans on Wall Street as high rates pose challenges to Main Street operationsSecond-quarter profits at Bank of America fell 7% from a year ago as its consumer operations wrestled with higher interest rates, but it was able to churn...
Read more »
Wall Street experts nearly unanimous on gold posting gains next week, Main Street sentiment firmly bullishThe Kitco News Team brings you the latest news, videos, analysis and opinions regarding Precious Metals, Crypto, Mining, World Markets and Global Economy.
Read more »
Nike posts quarterly sales that miss Wall Street estimatesNike Inc. reported quarterly sales that fell short of expectations — adding urgency to the world’s largest sportswear company’s efforts to strengthen ties with its retail partners and speed up its product development.
Read more »
J&J beats Wall Street estimates on strong drug sales(Reuters) -Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer...
Read more »
Stock market today: Wall Street trudges higher on bank earnings; US retail sales data arrives soonWall Street is logging tiny gains early Tuesday with earnings season revving up and upcoming U.S. retail sales data that could influence a decision by the...
Read more »